C. Cao

发表

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.

John T. Chang, Siddharth Singh, B. Sands, 2018, Gastroenterology.

Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome

Deepak L. Bhatt, F. Zannad, D. Holmes, 2014, Thrombosis and Haemostasis.

Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series

R. Bergman, C. Cobelli, C. Dalla Man, 2016, Diabetes Care.

Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial

J. Rosenstock, A. Lincoff, S. Nissen, 2018, Diabetes Care.

Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring

G. Bakris, Alfonso T. Perez, W. White, 2011, Journal of clinical hypertension.

Oral Antidiabetic Drugs: Bioavailability Assessment of Fixed‐Dose Combination Tablets of Pioglitazone and Metformin. Effect of Body Weight, Gender, and Race on Systemic Exposures of Each Drug

A. Karim, C. Cao, Zhen Zhao, 2007, Journal of clinical pharmacology.

Combining the G‐protein‐coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12‐week trial

C. Cao, J. Marcinak, X. V. Peng, 2017, Diabetes, obesity & metabolism.

The Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80 mg: Significant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure

Alfonso T. Perez, C. Cao, A. Perez, 2017, Journal of clinical hypertension.

Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo‐controlled study

C. Cao, J. Marcinak, Douglas Lee, 2017, Diabetes, obesity & metabolism.

Disposition Kinetics and Tolerance of Escalating Single Doses of Ramelteon, a High‐Affinity MT1 and MT2 Melatonin Receptor Agonist Indicated for Treatment of Insomnia

D. Tolbert, A. Karim, C. Cao, 2006, Journal of clinical pharmacology.

A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery

G. Raskob, B. Eriksson, A. Turpie, 2010, Thrombosis and Haemostasis.

Rapid Response to Vedolizumab Therapy in Biologic‐Naive Patients With Inflammatory Bowel Diseases

B. Feagan, J. Colombel, Abigail M. Wojtowicz, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Azilsartan in Patients With Mild to Moderate Hypertension Using Clinic and Ambulatory Blood Pressure Measurements

Alfonso T. Perez, C. Cao, A. Perez, 2017, Journal of clinical hypertension.

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*

Jon Cohen, G. Bernard, J. Vincent, 2010, Critical care medicine.

Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension

G. Bakris, Alfonso T. Perez, W. White, 2011, Hypertension.

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies

W. Sandborn, P. Dulai, M. Osterman, 2019, Digestive Diseases and Sciences.

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

John T. Chang, Siddharth Singh, B. Sands, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure

G. Bakris, Alfonso T. Perez, W. White, 2011, Journal of clinical hypertension.

Adapting the Goal Attainment Approach for Major Depressive Disorder

S. Parikh, M. Opler, C. François, 2019, Neurology and Therapy.

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

C. Burant, M. Vakilynejad, C. Cao, 2012, The Lancet.

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril

G. Bakris, Alfonso T. Perez, W. White, 2013, Journal of Human Hypertension.

A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone

P. Sever, C. Cao, A. Juhasz, 2018, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension

G. Bakris, W. White, D. Sica, 2014, Blood pressure monitoring.

Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension

G. Bakris, Alfonso T. Perez, W. White, 2017, Journal of clinical hypertension.

Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis

W. Sandborn, R. Panaccione, P. Dulai, 2018, Journal of Crohn's & colitis.

P051 Lower incidence of herpes zoster in vedolizumab-treated vs. tofacitinib-treated patients with ulcerative colitis

F. Caldera, K. Lasch, C. Cao, 2018 .

Vedolizumab Demonstrates Early Symptomatic Improvement in Ulcerative Colitis: A GEMINI 1 Post hoc Analysis: 670

B. Feagan, J. Colombel, Abigail M. Wojtowicz, 2017 .

Influence Diagnostics of a Region of Interest in Multi-regional Clinical Trials

Kazuhiko Kuribayashi, C. Cao, 2022, Therapeutic Innovation and Regulatory Science.